Trial Profile
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2023
Price :
$35
*
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms ECZTRA 1
- Sponsors LEO Pharma
- 07 Oct 2023 Results of pooled post hoc analysis ((n = 1328, from two phase III trials, ECZTRA 1 and 2) assessing the impact of tralokinumab versus placebo on other clinically meaningful parameters in patients not achieving IGA 0/1 at week 16 published in the American Journal of Clinical Dermatology
- 08 Sep 2023 Results of pooled analysis from ECZTRA 1 and 2 , exploring the long-term efficacy of tralokinumab for AD, published in the American Journal of Clinical Dermatology
- 23 Aug 2023 Results of pooled post hoc analysis from ECZTRA 1 and 2 and ECZTRA 3 assessing assess safety published in the JAMA Dermatology.